Framework
The Three-Sleeve Compounding Framework
The BioCompound is built around one system.
It is designed to identify biotech companies with long-duration compounding potential — and to track them under consistent conditions over time.
This is not a collection of ideas. It is a structured process applied the same way, every time.
The Objective
The framework answers a single question:
Which biotech companies can compound over a 7–10 year period without relying on external capital or binary outcomes?
To answer that, every company is evaluated against the same criteria and placed into a defined sleeve.
The Three Sleeves
7–10 Year Sleeve — The Compounding Engine
Companies with established commercial products, durable market positions, multi-year revenue visibility, internal funding capacity, and reduced binary risk.
2–3 Year Sleeve — Graduation Candidates
Companies with credible paths toward 7–10 year status, but where one or more conditions still need to be confirmed.
Watch List — The Entry Funnel
Companies under evaluation. Movement out of the Watch List is based on observable progress, not narrative. Watch List entries carry no allocation by definition.
The Five Criteria
Every company is evaluated against five criteria:
- Commercial validation
- Market position
- Revenue visibility
- Financial structure
- Exposure to binary outcomes
The full framework explains how each criterion is defined, how companies are assessed, and how movement between sleeves is determined.
The Model Allocation
The framework includes a hypothetical model capital representation shown at the sleeve level.
It is designed to illustrate how the framework evolves over time — not to present a transaction log, performance report, or instruction set for any individual portfolio.
What This Framework Is Not
The BioCompound framework is not a signal service, a trading system, a managed portfolio, or a prediction engine.
It does not tell you what to buy or when.
It shows how one system evaluates biotech companies consistently over time.
Why This Approach Exists
Biotech is often treated as a category defined by volatility and binary outcomes.
The framework isolates a subset of companies that behave differently:
- durable revenue
- defensible positions
- long-term visibility
These are rare — but identifiable.
Read the Full Framework
The Full Framework methodology document is delivered with the VRTX demonstration request, every standalone deep dive purchase, and both paid subscription tiers.